TLDR Tailored treatment is crucial for elderly men with BPH due to potential risks and benefits of medications.
The document reviewed medical therapies for treating benign prostatic hyperplasia (BPH) in elderly men, highlighting special considerations for this demographic. It discussed various medications, including Tamsulosin, which was noted for potential increased risks of dementia in older males. The FORTA classification system evaluated medications like Fesoterodine, Finasteride, and Dutasteride as beneficial for BPH treatment. The document also referenced studies on the efficacy and safety of drugs like tadalafil and combination therapies, emphasizing the importance of tailored treatment approaches for older adults with BPH.
90 citations
,
March 2017 in “JAMA Internal Medicine” Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.
111 citations
,
June 2015 in “Age and Ageing” Dutasteride, fesoterodine, and finasteride are beneficial for older patients, while most other drugs should be used cautiously or avoided.
1707 citations
,
December 2003 in “The New England Journal of Medicine” Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
January 2018 in “Surgical and Cosmetic Dermatology” 5-alpha reductase inhibitors like finasteride and dutasteride are effective for treating enlarged prostate and male pattern hair loss.
August 2016 in “Journal of Investigative Dermatology” April 2013 in “The FASEB Journal” Dutasteride showed some prevention of prostate issues but also had limitations, especially with high-grade tumors.
1 citations
,
November 2010 in “Anticancer Research” Finasteride and dutasteride both increase chromogranin A levels similarly.
20 citations
,
January 2004 in “PubMed” Dutasteride reduces DHT more than finasteride, but both drugs improve BPH symptoms similarly.
